“EP262 and EP547 are complementary additions to our portfolio, providing an opportunity to leverage our expertise, address the needs of patients with inflammatory diseases, and additional potential launch opportunities starting in 2029,” said Hervé Hoppenot, Incyte’s CEO.
With this update, Cantor Fitzgerald has initiated coverage on Incyte with a Neutral rating.
The Cantor…

#ep262andep547#hervéhoppenot#incyte#cantorfitzgerald#cantor#jakafi#opzelura#morphosysags